Skip to Content
You are currently on the new version of our website. Access the old version .
CancersCancers
  • Review
  • Open Access

7 August 2022

15 Pages

The Challenging Management of Craniopharyngiomas in Adults: Time for a Reappraisal?

,
,
,
,
,
,
,
and
1
Aix Marseille University, MMG, INSERM U1251, MAEMARA Institute, Department of Endocrinology, CRMR HYPO, 13385 Marseille, France
2
Department of Neurosurgery, University Hospital of Erlangen, 91052 Erlangen, Germany
3
Aix Marseille University, MMG, INSERM U1251, MAEMARA Institute, Department of Neurosurgery, CRMR HYPO, 13385 Marseille, France
4
Centre for Endocrinology, Barts and the London School of Medicine, London OX1 2JD, UK
This article belongs to the Special Issue Rare Primary Brain Tumors in Adults

Simple Summary

Craniopharyngiomas (CPs) currently represent one of the most challenging diseases to deal with in the group of skull base tumors. Due to their location near, within, or surrounding the pituitary gland and stalk, CPs can be revealed by pituitary tumor syndrome and/or symptoms of hormonal deficiencies. Furthermore, surgery, which represents the first-line therapy, almost always results in hypopituitarism, diabetes insipidus and, in the case of hypothalamic involvement by the tumor, the occurrence of hypothalamic syndrome. The latter is characterized by intractable weight gain associated with severe morbid obesity, memory impairment, attention deficit, reduced impulse control and, eventually, increased risk of cardiovascular and metabolic disorders. Recent progress made in the understanding of the molecular pathways involved in CPs tumorigenesis paves the way for promising alternative therapeutic approaches and diagnostic procedures. Taken together, they lay the groundwork for new paradigms in the management of CPs in adults.

Abstract

Craniopharyngiomas (CPs) are rare tumors of the skull base, developing near the pituitary gland and hypothalamus and responsible for severe hormonal deficiencies and an overall increase in mortality rate. While surgery and radiotherapy represent the recommended first-line therapies for CPs, a new paradigm for treatment is currently emerging, as a consequence of accumulated knowledge concerning the molecular mechanisms involved in tumor growth, paving the way for anticipated use of targeted therapies. Significant clinical and basic research conducted in the field of CPs will undoubtedly constitute a real step forward for a better understanding of the behavior of these tumors and prevent associated complications. In this review, our aim is to summarize the multiple steps in the management of CPs in adults and emphasize the most recent studies that will contribute to advancing the diagnostic and therapeutic algorithms.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.